About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT01229085

Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis

To evaluate the efficacy of the combination of mometasone furoate 0.1% and Salicylic Acid 5% in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.

Lead sponsor: Azidus Brasil•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Azidus Brasil

Phase III clinical trial, systematic sampling, open-label study that evaluated the efficacy of the combination of mometasone furoate 0.1% and 5% salicylic acid in 71 patients with lesions of mild to moderate psoriasis treated for up to 45 days or less than this, at the discretion of the investigator. The results were statistically analyzed and investigational data and their conclusions are referred to in this report.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults of both sexes, regardless of color or social class;
•Age 18 or older, with good mental health;
•Psoriasis patients with mild to moderate;
•Patients who agreed to participate and signed the
•Clarified (appendix);
•Patients who agreed to return for follow-up visits.

Exclusion Criteria

•Patients who were making use of biologics, corticosteroids or nonsteroidal anti-inflammatory and non-steroid, or who made use of these topical medications until 15 days before inclusion or 30 days before inclusion when the administration was orally;
•Patients who were exposed to the sun 15 days before the study began or during the course of the same;
•Patients who were making use of acetaminophen;
•Patients who did not agree to the terms described in the IC informed consent, - Patients who also had psoriatic plaques of skin disorders caused by fungi or bacteria and they were making use of antibiotic or antifungal;
•Lions and other types of skin damage that was not psoriasis;
•Pregnant and nursing women;
•Patients using oral anticoagulants.

Related studies

RECRUITINGPhase 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792 · Plaque Psoriasis

RECRUITINGPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · Psoriasis, Overweight or Obesity

RECRUITINGPhase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234 · Psoriasis

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048 · Psoriasis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 27, 2010Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment71

Start dateSep 2006

Last updatedOct 27, 2010

Condition

Locations shown

LAL Clinica Pesquisa e Desenvolvimento Ltda.

Valinhos, São Paulo

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 27, 2010Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions